Sign in

Promita Ghosh (she/her)

@ghoshonthemove.bsky.social
160 followers 542 following 1 posts

Biochemistry PhD student at McGill. Studies and loves talking about RTKs in lung cancer. Coffee and cafe lover. Also, black hole enthusiast.

PostsRepliesMedia
Reposted by Promita Ghosh (she/her)
amitava banerjee @amitava-immuno.bsky.social · 10/09/2025
Authoritative review from The one and only @ghoshonthemove.bsky.social ☺️on her doctoral work on NSCLC 🫁 @mcgillgci.bsky.social portlandpress.com/biochemsoctr... Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers
portlandpress.com
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...
011
Promita Ghosh (she/her) @ghoshonthemove.bsky.social · 10/09/2025
Why does MET exon 14 skipping matter? It is more than a mere oncogenic mutation!😱🫁 Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond @mcgillgci.bsky.social portlandpress.com/biochemsoctr...
portlandpress.com
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...
031
Reposted by Promita Ghosh (she/her)
amitava banerjee @amitava-immuno.bsky.social · 25/07/2025
Got new #TCR-pMHC data to send our way into BATCAVE? Wanna try BATMAN to predict targets of your #TCR? We would love to hear from you! 💽Database+codes: github.com/meyer-lab-cs... 💻BATMAN software + tutorials: github.com/meyer-lab-cs... 🦇Lets decode TCR-pMHC logic, one mutation at a time🦇
github.com
GitHub - meyer-lab-cshl/BATMAN-paper: Bayesian inference of Activation of TCR by Mutant Antigens
Bayesian inference of Activation of TCR by Mutant Antigens - meyer-lab-cshl/BATMAN-paper
0137
Reposted by Promita Ghosh (she/her)
Soragni:Lab @alice.soragnilab.com · 03/06/2025
Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies www.nature.com/articles/s41...
nature.com
Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer
Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...
13414
Reposted by Promita Ghosh (she/her)
Cell Chemical Biology @cp-cellchembiol.bsky.social · 18/04/2025
Streptomycin Targets Tumor-Initiating Cells by Disrupting the Oxidative Phosphorylation (OXPHOS) Pathway by Hélène Guillorit, @mariaduca-cnrs.bsky.social, Françoise Macari, Alexandre David et al at @cnrs.fr @inserm.fr dlvr.it/TKDrwY
052
Reposted by Promita Ghosh (she/her)
Nature @nature.com · 18/04/2025
Nature research paper: Generation of human adult hepatocyte organoids with metabolic functions go.nature.com/43WXrX7
go.nature.com
Generation of human adult hepatocyte organoids with metabolic functions - Nature
The combined activation of Wnt and STAT3 signalling enables long-term self-renewal of human hepatocyte organoids, maintaining hepatic identity, supporting gene editing and offering therapeutic potential for liver disease through enhanced functionality, structure and metabolic competency.
1224
Reposted by Promita Ghosh (she/her)
Science Magazine @science.org · 18/04/2025
Can blocking “jumping genes” treat diseases and aging? The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4
scim.ag
Could blocking ‘jumping genes’ help fight disease and aging?
The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own
04611